Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia.
Lönnerholm G, Thörn I, Sundström C, Frost BM, Flaegstad T, Heyman M, Jonsson OG, Harila-Saari A, Madsen HO, Porwit A, Schmiegelow K, Söderhäll S, Wesenberg F, Vettenranta K, Larsson R, Forestier E. Lönnerholm G, et al. Leuk Res. 2011 Apr;35(4):472-8. doi: 10.1016/j.leukres.2010.09.001. Epub 2010 Oct 18. Leuk Res. 2011. PMID: 20961616
Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia.
Frost BM, Nygren P, Gustafsson G, Forestier E, Jonsson OG, Kanerva J, Nygaard R, Schmiegelow K, Larsson R, Lönnerholm G; Nordic Society for Paediatric Haematology and Oncology. Frost BM, et al. Among authors: lonnerholm g. Br J Haematol. 2003 Aug;122(3):376-85. doi: 10.1046/j.1365-2141.2003.04442.x. Br J Haematol. 2003. PMID: 12877664 Free article.
In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.
Lönnerholm G, Thörn I, Sundström C, Frost BM, Abrahamsson J, Behrendtz M, Heldrup J, Jacobsson S, Li A, Olofsson T, Porwit A, Söderhäll S, Larsson R, Forestier E. Lönnerholm G, et al. Leuk Res. 2009 Jan;33(1):46-53. doi: 10.1016/j.leukres.2008.06.012. Epub 2008 Jul 17. Leuk Res. 2009. PMID: 18639340
Monitoring minimal residual disease with flow cytometry, antigen-receptor gene rearrangements and fusion transcript quantification in Philadelphia-positive childhood acute lymphoblastic leukemia.
Thörn I, Botling J, Hermansson M, Lönnerholm G, Sundström C, Rosenquist R, Barbany G. Thörn I, et al. Among authors: lonnerholm g. Leuk Res. 2009 Aug;33(8):1047-54. doi: 10.1016/j.leukres.2008.11.031. Epub 2009 Jan 20. Leuk Res. 2009. PMID: 19157547 Clinical Trial.
DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia.
Milani L, Lundmark A, Kiialainen A, Nordlund J, Flaegstad T, Forestier E, Heyman M, Jonmundsson G, Kanerva J, Schmiegelow K, Söderhäll S, Gustafsson MG, Lönnerholm G, Syvänen AC. Milani L, et al. Among authors: lonnerholm g. Blood. 2010 Feb 11;115(6):1214-25. doi: 10.1182/blood-2009-04-214668. Epub 2009 Nov 25. Blood. 2010. PMID: 19965625 Free article.
DNA methylation holds prognostic information in relapsed precursor B-cell acute lymphoblastic leukemia.
Borssén M, Nordlund J, Haider Z, Landfors M, Larsson P, Kanerva J, Schmiegelow K, Flaegstad T, Jónsson ÓG, Frost BM, Palle J, Forestier E, Heyman M, Hultdin M, Lönnerholm G, Degerman S. Borssén M, et al. Among authors: lonnerholm g. Clin Epigenetics. 2018 Mar 5;10:31. doi: 10.1186/s13148-018-0466-3. eCollection 2018. Clin Epigenetics. 2018. PMID: 29515676 Free PMC article.
144 results